PATH Injectables Access Collaborative 3.0

The purpose of the Access Collaborative (AC) is to advance the introduction and scale-up of subcutaneous (SC) depot medroxyprogesterone acetate (DMPA) – or DMPA-SC, including self-injection (SI). The AC is a coordination and TA effort that aims to ensure the sustainable availability of DMPA-SC as part of an expanded range of contraceptive methods delivered through informed choice programming. DMPA-SC offers a safe and effective injectable contraceptive that clients can, once trained, inject themselves if they choose.

At the core of the AC’s mission is the belief that when women and adolescents have access to a variety of contraceptives, including those they can manage themselves, they are more likely to find and consistently use a method that meets their needs and ultimately realize their reproductive intentions. AC work includes continuous TA for locally-led scale-up of DMPA-SC and SI in 11 focus countries and short-term TA in 23 non-focus countries; data consolidation and analytics to drive effective injectables category management and donor/stakeholder coordination, knowledge management, and learning exchange to catalyze adoption of evidence-based practices related to DMPA-SC and SI globally. Global workstreams—led by AC-PATH, with participation from across the consortium members—will also function to offer self-serve resources and opportunities to countries preparing for, or in the early stages of, introducing DMPA-SC/SI.